Fecal β-defensin-2 levels were about 56% higher in children with active celiac disease compared to healthy children, pointing to an activated innate immune defense in the gut.
99.6 vs 64.0 ng/mLFecal β-defensin-2 levels in children with celiac disease versus healthy controls
What the researchers found
Children with active celiac disease had significantly elevated fecal β-defensin-2 levels (99.6 vs 64.0 ng/mL, p<0.001) and higher anti-BPI antibodies compared to healthy controls. Fecal calprotectin and β-defensin-2 were moderately correlated (r=0.69), and β-defensin-2 weakly correlated with anti-BPI antibodies (r=0.35). These findings suggest that antimicrobial peptides are part of the gut's innate immune response in celiac disease.
Why it matters
Celiac disease diagnosis and monitoring still rely heavily on invasive biopsies and antibody tests. Fecal biomarkers like β-defensin-2 could offer a non-invasive way to assess intestinal inflammation and immune activation in children with celiac disease, potentially helping track disease activity without repeated endoscopies.
The numbers in context
n=108 (76 CD, 32 controls) · β-defensin-2: 99.6 vs 64.0 ng/mL (p<0.001) · Calprotectin-defensin correlation r=0.69 · Defensin-anti-BPI correlation r=0.35
How the study worked
Case-control study of 76 children (ages 2-10) with recently diagnosed celiac disease and 32 age-matched healthy controls. Measured fecal β-defensin-2 and calprotectin levels in stool samples and anti-BPI antibodies in blood serum. Correlations between markers assessed using Pearson coefficient.
Who was studied
Children ages 2-10 with recently diagnosed celiac disease and age-matched healthy controls
What this study cannot tell us
Relatively small sample size, especially the control group (32 children). Cross-sectional design cannot determine whether elevated AMPs are a cause or consequence of celiac inflammation. Did not follow patients after starting a gluten-free diet to see if biomarkers normalized. Age range limited to 2-10 years.
How to read the evidence
Moderate evidence: case-control design with objective biomarker measurements and appropriate controls, but limited by small sample size, cross-sectional design, and lack of longitudinal follow-up.
When this study was published
Published in 2022. Relevant as research into non-invasive celiac biomarkers continues to advance, and antimicrobial peptide roles in autoimmune gut conditions remain an active area of investigation.
The bigger picture
Most celiac disease research focuses on the adaptive immune response (antibodies against gluten). This study highlights the role of innate immunity — the body's first-line defense — through antimicrobial peptides. Understanding how defensins and other AMPs respond in celiac disease could reveal new aspects of disease mechanisms and lead to non-invasive stool-based monitoring tools, which would be especially valuable for pediatric patients who are difficult to subject to repeated biopsies.
Questions still open
- Do fecal β-defensin-2 levels normalize when children with celiac disease follow a strict gluten-free diet?
- Could β-defensin-2 serve as a reliable non-invasive biomarker for monitoring celiac disease activity over time?
- Are antimicrobial peptide levels also elevated in adults with celiac disease, or is this specific to pediatric patients?
Common questions
What is β-defensin-2 and why is it elevated in celiac disease?
Could a stool test replace a biopsy for diagnosing celiac disease?
Read the original research
The Activity of Antimicrobial Peptides in Pediatric Celiac Disease.
Frontiers in pediatrics, 10, 873793
Citation
Kamilova, Altinoy T; Azizova, Gulnoza K; Umarnazarova, Zulkhumar E; Abdullaeva, Dilrabo A; Geller, Svetlana I. (2022). The Activity of Antimicrobial Peptides in Pediatric Celiac Disease.. Frontiers in pediatrics, 10, 873793. https://doi.org/10.3389/fped.2022.873793